Compare Enphase Energy Inc (ENPH) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Merck & Co., Inc. — how do they compare? Enphase Energy Inc trades at $33.19 (market cap $4.35B), while Merck & Co., Inc. trades at $142.88 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 80.8× Enphase Energy Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Merck & Co., Inc. for 98 Days on average.
| ENPH | MRK | |
|---|---|---|
Market Cap | $4.35B | $351.28B |
Volume | 5,068,595 | 7,969,665 |
Sector | Energy | Health |
52-Week High | $72.33 | $156.43 |
52-Week Low | $26.12 | $82.49 |
Typical Hold Time | 72 Days | 98 Days |
Enterprise Value | $3.99B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $33.50, down 1.21% with bearish technical signals and mixed earnings performance. The stock shows declining revenue from $2.3B in 2023 to $1.47B in 2025, though net margins improved to 10.09%. Recent developments include IQ Meter Collar approvals and solid-state transformer production for AI data centers, providing potential growth catalysts amid solar sector volatility.
Outlook remains cautious with analyst consensus at $42.90 (28% upside) but recent earnings misses and high borrowing costs for solar projects pose near-term risks. The stock offers exposure to energy technology innovation but faces competitive pressure and macroeconomic headwinds affecting renewable energy demand.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
